Gleason Group’s ImmunityBio IBRX Stock Holding History

Gleason Group’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,000	Closed	-$10K	–	208
2021 Q3	$10K	Buy	+1,000	New	+$11K	﹤0.01%	161

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Gleason Group's IBRX Position: Q4 2021 in Review

Gleason Group sold out of ImmunityBio (IBRX) in Q4 2021, closing a stake of 1,000 shares — an estimated $10K sold.

Gleason Group first reported a position in IBRX in Q3 2021 and held it in 1 quarter. The position peaked at $10K in Q3 2021. 141 funds tracked by Wall St. Rank hold IBRX as of Q4 2021.

Gleason Group reported no remaining ImmunityBio position as of Q4 2021 after selling out during the quarter.
Gleason Group sold 1,000 ImmunityBio shares in Q4 2021, an estimated $10K.
Gleason Group first reported a position in ImmunityBio in Q3 2021 and held it in 1 quarter.
Gleason Group's ImmunityBio position peaked at $10K in Q3 2021.
141 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2021.

Based on Gleason Group's 13F filing for Q4 2021, filed 18 Jan 2022.